Card image

Infectious Complications in Patients with Hematologic Malignancy and in Recipients of Hematopoietic Stem Cell Transplantation

Infectious Complications in Patients with Hematologic Malignancy and in Recipients of Hematopoietic Stem Cell Transplantation

Infectious Complications in Patients with Hematologic Malignancy and in Recipients of Hematopoietic Stem Cell Transplantation

  • Editor: Dr. Asma Marzouq Al-Jasser  
  • Publisher: OMICS International
  • Chapter 1      
    Infectious complications in patients with acute myeloid leukemia. Relation of these infections to: the primary disease and to the therapy, including HSCT, given to control the disease will be discussed in detail. Invasive fungal infections in these patients will be highlighted.
    Authors:

  • Chapter 2      
    Infectious complications in patients with chronic lymphocytic leukemia. Relation of these infections to: the primary disease [immunosuppressive illness, hypogammmaglobulinemia and old age] and to the therapy [chemotherapy, monoclonal antibodies and HSCT] given to control the disease will be discusse
    Authors:

  • Chapter 3      
    Infectious complications in patients with hairy cell leukemia. Relation of these infections to: the primary disease and to the therapy given to control the disease will be discussed in detail. Role of infection prophylaxis will also be highlighted.
    Authors:

  • Chapter 4      
    Infectious complications in recipients of various forms of HSCT e.g. autologous HSCT, non-myeloablative form of HSCT and cord blood transplantation will be discussed in detail. Role of infection prophylaxis in these forms of HSCT will also be highlighted.
    Authors:

  • Chapter 5      
    Infections involving central venous catheters in patients with HM and in recipients of HSCT will be discussed. Implications of the type of central venous catheter used and indications for removal of these catheters will be discussed in detail.
    Authors:

  • Chapter 6      
    Infectious complications related to intensive cytotoxic chemotherapy, targeted therapies and monoclonal antibodies e.g. rituximab, alemtuzumab, fludarabine in patients with HM and in recipients of HSCT. Role of regular screening and prophylactic antimicrobial therapy will be discussed.
    Authors:

  • Chapter 7      
    Bacterial infections and bacteremia in patients with HM and in recipients of HSCTs. Topics will cover: Gram-positive as well as Gram-negative bacterial infections in addition to multi-drug resistant organisms e.g. Stenotrophomonas maltophilia and Acinetobacter baumannii. Predisposing factors, compli
    Authors:

  • Chapter 8      
    Candida [albicans and non-albicans] infections and candidemia in patients with HM and in recipients of HSCT. Risk factors, serological and cultural techniques, complications and management of these infections will be discussed in detail.
    Authors:

  • Chapter 9      
    Invasive fungal infections in patients with HM and in recipients of HSCT. Predisposing factors, complications, diagnostic techniques and available therapeutic modalities will be discussed in detail.
    Authors:

  • Chapter 10      
    Viral infections in patients with HM and in recipients of HSCT. Predisposing factors, complications, diagnostic techniques and therapeutic options will be discussed in detail. Focus will be on cytomegalovirus [CMV] infections and CMV disease in recipients of HSCT. Other viral infections e.g. varicel
    Authors:

  • Chapter 11      
    Septicemia and septic shock in patients with HM and in recipients of various forms of HSCT. Risk factors, clinical manifestations, complications and managements of these serious complications will be discussed thoroughly.
    Authors:

  • Chapter 12      
    Infections caused by Mycobacterium tuberculosis and non-tuberculous Mycobacteria in patients with HM and in recipients of various forms of HSCT. Risk factors, clinical manifestations, complications and management of these infections will be discussed in detail.
    Authors:

  • Chapter 13      
    Infections caused by zoonotic, parasitic and endemic infections occurring in patients with HM and in recipients of various forms of HSCT. Risk factors, clinical manifestations, complications and management of such infections will be discussed thoroughly.
    Authors:

  • Chapter 14      
    Febrile neutropenia in patients with HM and in recipients of HSCT. Predisposing factors, complications and managements of febrile neutropenia will be discussed in detail. Focus will be on empirical, pre-emptive and culture-guided therapies.
    Authors:

  • Chapter 15      
    Neutropenic colitis in patients with HM and in recipients of HSCT. Predisposing factors, complications and management of this acute abdominal emergency will be discussed in detail. Focus will be on supportive care, antimicrobial therapy and radiological investigations.
    Authors:

  • Dr. Asma Marzouq Al-Jasser

Follow us on